RGPX · As filed with the SEC
Regenerex Pharma cash flow statement, by fiscal year
The statement as Regenerex Pharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
STATEMENTS OF CASH FLOWS · USD
| USD | FY2024 Year ended Mar 31, 2025 | FY2023 Year ended Mar 31, 2024 | FY2023 Year ended Mar 31, 2023 | FY2022 Year ended Mar 31, 2022 |
|---|---|---|---|---|
| Cash Flows from Operating Activities: | ||||
| Net Income | (2,527,041) | (3,543,827) | (137,330) | (195,591) |
| Loss on discontinued operations | — | — | — | 5,510 |
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||||
| Depreciation Expense | 3,054 | 4,278 | 3,420 | 3,529 |
| Effect of Exchange Rate on Cash | — | — | — | 4,751 |
| Foreign currency adjustments | (5,728) | (2,636) | (25,629) | — |
| Stock-Based Compensation Expense | 132,662 | 211,698 | — | 45,000 |
| Research and Development Expense | — | 2,400,000 | — | — |
| Non-cash interest related to Note extension | 240,000 | — | — | — |
| Net Cash from Operating Activities | 19,807 | 53,719 | — | — |
| Changes in operating assets and liabilities: | ||||
| Prepaid expenses | 2,190 | (2,540) | 5,256 | (4,043) |
| Change in Accounts Payable | — | — | 78,119 | 76,432 |
| Net Cash from Operating Activities | — | — | (76,164) | (64,412) |
| Net Cash from Operating Activities | — | — | — | (5,510) |
| Accounts payable | 187,915 | 159,641 | — | — |
| Accrued compensation | 330,773 | 290,655 | — | — |
| Other accrued liabilities | (8,983) | (28,536) | — | — |
| Net Cash from Operating Activities | (1,625,351) | (457,548) | (76,164) | (69,922) |
| Website development | — | — | — | (8,600) |
| Computer equipment | — | — | (1,398) | — |
| Purchase of furniture and computer equipment | (1,228) | (6,299) | — | — |
| Net Cash from Investing Activities | (1,228) | (6,299) | (1,398) | (8,600) |
| Related party advances | — | — | 200 | — |
| Proceeds from Debt Issuance | — | — | 37,857 | 73,565 |
| Proceeds from Debt Issuance | 9,962 | 3,490 | 40,500 | 695 |
| Net Cash from Financing Activities | — | (10,000) | — | — |
| Other Affiliates | — | 3,844 | — | — |
| Affiliated Entity | 284,460 | 120,000 | — | — |
| Payments of notes payable to shareholders | (201,562) | — | — | — |
| Net Cash from Financing Activities | (113,628) | (47,500) | (2,500) | — |
| Proceeds from Stock Issuance | 2,300,000 | 393,250 | — | — |
| Net cash provided by financing activities | 2,279,232 | 463,084 | 76,057 | 74,260 |
| Net Change in Cash | 652,653 | (763) | (1,505) | (4,262) |
| Cash and cash equivalents, beginning of year | — | — | 2,640 | 6,902 |
| Cash and cash equivalents, end of year | — | — | — | 2,640 |
| Cash and cash equivalents, beginning of year | 372 | 1,135 | 2,640 | — |
| Cash and cash equivalents, end of year | 653,025 | 372 | 1,135 | — |
| Accrued interest converted into note payable to shareholder | — | — | — | 42,818 |
| Interest Expense | 27,568 | — | — | — |
| Accrued interest converted into notes payable to shareholder | 82,232 | 66,469 | 30,294 | — |
| Net Cash from Operating Activities | — | — | — | 150,000 |
| Accrued interest converted into note payable | — | 52,545 | — | — |
| Accrued interest converted into notes payable to related parties | 24,771 | — | — | — |
| Operating lease, ROU asset and liabilities | 52,203 | 953,355 | — | — |
| Note payable issued for research and development | — | 2,400,000 | — | — |
| Note payable issued for Note extension | 240,000 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.